---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-021059"
form_type: "8-K"
ticker: null
cik: "0000810509"
company_name: "NAVIDEA BIOPHARMACEUTICALS, INC."
filed_at: "2023-07-28T23:59:59+00:00"
generated_at: "2026-06-12T23:27:06.938261+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Navidea appoints Craig Dais as CFO; stockholders approve reverse split and preferred conversion

## Summary
- Joseph Meyer resigns as Director, Finance and Accounting; last day August 11, 2023.
- Craig Dais appointed CFO effective July 28, 2023; base salary $200k, bonus target 20%, stock option target 150k/year.
- Stockholders approve reverse stock split (ratio 1:20 to 1:50) to maintain NYSE American listing; 47.9M for, 16.5M against.
- Stockholders approve issuance of >19.99% shares to Vice Chairman John K. Scott Jr. upon Series J conversion, resulting in change of control; 39.9M for, 15.9M against, 8.4M broker non-votes.

## SEC filing metadata
- accession: 0001437749-23-021059
- form_type: 8-K
- cik: 0000810509
- company_name: NAVIDEA BIOPHARMACEUTICALS, INC.
- filed_at: 2023-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/0001437749-23-021059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/navb20230728_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-021059
- JSON: https://secwatch.observer/filing/0001437749-23-021059.json
- Plain text: https://secwatch.observer/filing/0001437749-23-021059.txt

## Key facts
- Executive change
  Craig Dais was appointed as Chief Financial Officer at NAVIDEA BIOPHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On July 26, 2023 the Board of Directors (the “Board”) of the Company appointed Craig Dais, age 57, as the Company’s Chief Financial Officer, effective upon his start date of July 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/0001437749-23-021059-index.htm
- Executive change
  Joseph W. Meyer resigned as Director, Finance and Accounting at NAVIDEA BIOPHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director, Finance and Accounting
  source text: On July 24, 2023, Joseph W. Meyer, Director, Finance and Accounting, Principal Financial Officer and Principal Accounting Officer of Navidea Biopharmaceuticals, Inc. (the “Company”), informed the Company of his resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/0001437749-23-021059-index.htm
- Shareholder Votes
  NAVIDEA BIOPHARMACEUTICALS, INC. shareholders approved Preferred Stock Conversion and Change of Control Proposal at the 2023-07-27 meeting.
  - Outcome: passed
  - Meeting: 2023-07-27
  source text: The Preferred Stock Conversion and Change of Control Proposal was approved by votes as follows: For Against Abstain 39,987,334 15,937,845 337,284 There were 8,441,135 broker non-votes on the Preferred Stock Conversion and Change of Control Proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/0001437749-23-021059-index.htm
- Shareholder Votes
  NAVIDEA BIOPHARMACEUTICALS, INC. shareholders approved Reverse Stock Split Proposal at the 2023-07-27 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-07-27
  source text: The Reverse Stock Split Proposal was approved by votes as follows: For Against Abstain 47,907,056,197 16,512,206,711 349,038,690 There were no broker non-votes on the Reverse Stock Split Proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/0001437749-23-021059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.